Skip to Content

Imprida HCT

Active Substance: amlodipine / valsartan / hydrochlorothiazide
Common Name: amlodipine / valsartan / hydrochlorothiazide
ATC Code: C09DB03
Marketing Authorisation Holder: Novartis Europharm Ltd.
Active Substance: amlodipine / valsartan / hydrochlorothiazide
Status: Withdrawn
Authorisation Date: 2009-10-15
Therapeutic Area: Hypertension
Pharmacotherapeutic Group: Angiotensin II antagonists, other combinations

Therapeutic Indication

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

The marketing authorisation for Imprida HCT has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.


Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.